



A SYSTEMATIC REVIEW: CURRENT TRENDS OF TYPE 2 DIABETES MELLITUS

Aditya Tripathi, Arshi Fatima, Abhinav Verma, Shiv Shankar*, Mohammad Zeeshan Qadari and Chandra Prakash Gupta

R.C.C College of Pharmacy Basti, UP, India.

*Corresponding Author: Shiv Shankar

R.C.C College of Pharmacy Basti, UP, India.

Article Received on 01/08/2023

Article Revised on 21/08/2023

Article Accepted on 10/09/2023

ABSTRACT

Type 2 diabetes mellitus (DM) is a chronic metabolic disorder in which prevalence has been increasing steadily all over the world. As a result of this trend, it is fast becoming an epidemic in some countries of the world with the number of people affected expected to double in the next decade due to increase in ageing population, thereby adding to the already existing burden for healthcare providers, especially in poorly developed countries. This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications. Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment. Only articles in English were included. Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Association (ADA) criteria which include both clinical and laboratory parameters. No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers like metformin, a biguanide that reduces insulin resistance, is still the recommended first line medication especially for obese patients. Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11 β -hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine. Inhaled insulin was licensed for use in 2006 but has been withdrawn from the market because of low patronage.

KEYWORDS: Type 2 diabetes mellitus, Diagnosis, Management, Newer drugs.

INTRODUCTION

Diabetes mellitus (DM) is probably one of the oldest diseases known to man. It was first reported in Egyptian manuscript about 3000 years ago.^[1] In 1936, the distinction between type 1 and type 2 DM was clearly made.^[2] Type 2 DM was first described as a component of metabolic syndrome in 1988.^[3] Type 2 DM (formerly known as non-insulin dependent DM) is the most common form of DM characterized by hyperglycemia, insulin resistance, and relative insulin deficiency.^[4] Type 2 DM results from interaction between genetic, environmental and behavioral risk factors.^[5,6]

People living with type 2 DM are more vulnerable to various forms of both short- and long-term complications, which often lead to their premature death. This tendency of increased morbidity and mortality is seen in patients with type 2 DM because of the commonness of this type of DM, its insidious onset and late recognition, especially in resource-poor developing countries like Africa.^[7]




Figure no. 1.

EPIDEMIOLOGY

It is estimated that 366 million people had DM in 2011; by 2030 this would have risen to 552 million.^[8] The

number of people with type 2 DM is increasing in every country with 80% of people with DM living in low- and middle-income countries. DM caused 4.6 million deaths in 2011.^[8] It is estimated that 439 million people would have type 2 DM by the year 2030.^[9] The incidence of type 2 DM varies substantially from one geographical region to the other as a result of environmental and lifestyle risk factors.^[10]

Literature search has shown that there are few data available on the prevalence of type 2 DM in Africa as a whole. Studies examining data trends within Africa point to evidence of a dramatic increase in prevalence in both rural and urban setting, and affecting both gender equally.^[11]

The majority of the DM burden in Africa appears to be type 2 DM, with less than 10% of DM cases being type 1 DM.^[11] A 2011 Centre for Disease Control and Prevention (CDC) report estimates that DM affects about 25.8 million people in the US (7.8% of the population) in 2010 with 90% to 95% of them being type 2 DM.^[12]

It is predicted that the prevalence of DM in adults of which type 2 DM is becoming prominent will increase in the next two decades and much of the increase will occur in developing countries where the majority of patients are aged between 45 and 64 years.^[13] It is projected that the latter will equal or even exceed the former in developing nations, thus culminating in a double burden as a result of the current trend of transition from communicable to non-communicable diseases.^[14]

LIFESTYLE, GENETICS AND MEDICAL CONDITION

Type 2 DM is due primarily to lifestyle factors and genetics.^[15] A number of lifestyle factors are known to be important to the development of type 2 DM. These are physical inactivity, sedentary lifestyle, cigarette smoking and generous consumption of alcohol.^[16] Obesity has been found to contribute to approximately 55% of cases of type 2 DM.^[17] The increased rate of childhood obesity between the 1960s and 2000s is believed to have led to the increase in type 2 DM in children and adolescents.^[18] Environmental toxins may contribute to the recent increases in the rate of type 2 DM. A weak positive correlation has been found between the concentration in the urine of bisphenol A, a constituent of some plastics, and the incidence of type 2 DM.^[19]

There is a strong inheritable genetic connection in type 2 DM, having relatives (especially first degree) with type 2 DM increases the risks of developing type 2 DM substantially. Concordance among monozygotic twins is close to 100%, and about 25% of those with the disease have a family history of DM.^[20] Recently, genes discovered to be significantly associated with developing type 2 DM, include *TCF7L2*, *PPARG*, *FTO*, *CNJ11*, *NOTCH2*, *WFS1*, *CDKAL1*, *IGF2BP2*, *SLC30A8*, *JAZF1*, and *HHEX*. *KCNJ11* (potassium inwardly

rectifying channel, subfamily J, member 11), encodes the islet ATP-sensitive potassium channel Kir6.2, and *TCF7L2* (transcription factor 7-like 2) regulates proglucagon gene expression and thus the production of glucagon-like peptide-1.^[21] Moreover, obesity (which is an independent risk factor for type 2 DM) is strongly inherited.^[22] Monogenic forms like Maturity-onset diabetes of the young (MODY), constitutes up to 5% of cases.^[23] There are many medical conditions which can potentially give rise to, or exacerbate type 2 DM. These include obesity, hypertension, elevated cholesterol (combined hyperlipidemia), and with the condition often termed metabolic syndrome (it is also known as Syndrome X, Reaven's syndrome).^[24] Other causes include acromegaly, Cushing's syndrome, thyrotoxicosis, pheochromocytoma, chronic pancreatitis, cancer, and drugs.^[25] Additional factors found to increase the risk of type 2 DM include aging,^[26] high-fat diets, and a less active lifestyle.^[27]

PATHOPHYSIOLOGY

Type 2 DM is characterized by insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual pancreatic beta-cell failure.^[28,29] This leads to a decrease in glucose transport into the liver, muscle cells, and fat cells. There is an increase in the breakdown of fat with hyperglycemia. The involvement of impaired alpha-cell function has recently been recognized in the pathophysiology of type 2 DM.^[30]

As a result of this dysfunction, glucagon and hepatic glucose levels that rise during fasting are not suppressed with a meal. Given inadequate levels of insulin and increased insulin resistance, hyperglycemia results. The incretins are important gut mediators of insulin release, and in the case of GLP-1, of glucagon suppression. Although GIP activity is impaired in those with type 2 DM, GLP-1 insulinotropic effects are preserved, and thus GLP-1 represents a potentially beneficial therapeutic option.^[30] However, like GIP; GLP-1 is rapidly inactivated by DPP-IV in vivo.

Two therapeutic approaches to this problem have been developed: GLP-1 analogues with increased half-lives, and DPP-IV inhibitors, which prevent the breakdown of endogenous GLP-1 as well as GIP.^[30] Both classes of agents have shown promise, with potential not only to normalize fasting and postprandial glucose levels but also to improve beta-cell functioning and mass. Studies are ongoing on the role of mitochondrial dysfunction in the development of insulin resistance and etiology of type 2 DM.^[31] Also very important is adipose tissue, as endocrine organ hypothesis (secretion of various adipocytokines, i.e., leptin, TNF-alpha, resistin, and adiponectin implicated in insulin resistance and possibly beta-cell dysfunction).^[30]

A majority of individuals suffering from type 2 DM are obese, with central visceral adiposity. Therefore, the adipose tissue plays a crucial role in the pathogenesis of

type 2 DM. Although the predominant theory used to explain this link is the portal/visceral hypothesis giving a key role in elevated non-esterified fatty acid concentrations, two new emerging theories are the ectopic fat storage syndrome (deposition of triglycerides in muscle, liver and pancreatic cells). These two hypotheses constitute the framework for the study of the interplay between insulin resistance and beta-cell dysfunction in type 2 DM as well as between our obesogenic environment and DM risk in the next decade.^[30]

DIAGNOSIS AND SCREENING

Tests for screening and diagnosis of DM are readily available. The test recommended for screening is the same as that for making diagnosis, with the result that a positive screen is equivalent to a diagnosis of pre-diabetes or DM.^[32] Although about 25% of patients with type 2 DM already have microvascular complications at the time of diagnosis suggesting that they have had the disease for more than 5 years at the time of diagnosis.^[33] It is still based on the American Diabetic Association (ADA) guidelines of 1997 or World Health Organization (WHO) National diabetic group criteria of 2006, which is for a single raised glucose reading with symptoms (polyuria, polydipsia, polyphagia and weight loss), otherwise raised values on two occasions, of either fasting plasma glucose (FPG) ≥ 7.0 mmol/L (126 mg/dL) or with an oral glucose tolerance test (OGTT), two hours after the oral dose a plasma glucose ≥ 11.1 mmol/L (200 mg/dL).^[32]

The 1997 ADA recommendations for diagnosis of DM focus on the FPG, while WHO focuses on the OGTT.³² The glycated hemoglobin (HbA1c) and fructosamine is also still useful for determining blood sugar control over time. However, practicing physicians frequently employ other measures in addition to those recommended. In July 2009, the International Expert Committee (IEC) recommended the additional diagnostic criteria of an HbA1c result $\geq 6.5\%$ for DM. This committee suggested that the use of the term pre-diabetes may be phased out but identified the range of HbA1c levels $\geq 6.0\%$ and $< 6.5\%$ to identify those at high risk of developing DM.^[34]

As with the glucose-based tests, there is no definite threshold of HbA1c at which normality ends and DM begins.^[32] The IEC has elected to recommend a cut-off point for DM diagnosis that emphasizes specificity, commenting that this balanced the stigma and cost of mistakenly identifying individuals as diabetic against the minimal clinical consequences of delaying the diagnosis in a patient with an HbA1c level $< 6.5\%$.^[34]

MANAGEMENT

Through lifestyle and diet modification. Studies have shown that there was significant reduction in the incidence of type 2 DM with a combination of maintenance of body mass index of 25 kg/m^2 , eating

high fibre and unsaturated fat and diet low in saturated and trans-fats and glycemic index, regular exercise, abstinence from smoking and moderate consumption of alcohol.^[5,16,35-37] Suggesting that majority of type 2 DM can be prevented by lifestyle modification. Patients with type 2 DM should receive a medical nutrition evaluation; lifestyle recommendations should be tailored according to physical and functional ability.^[38]

PHARMACOLOGICAL AGENTS

Biguanides

Biguanides, of which metformin is the most commonly used in overweight and obese patients, suppresses hepatic glucose production, increases insulin sensitivity, enhances glucose uptake by phosphorylating GLUT-enhancer factor, increases fatty acid oxidation, and decreases the absorption of glucose from the gastrointestinal tract.^[39] Research published in 2008 shows further mechanism of action of metformin as activation of AMP-activated protein kinase, an enzyme that plays a role in the expression of hepatic gluconeogenic genes.^[40] Due to the concern of development of lactic acidosis, metformin should be used with caution in elderly diabetic individuals with renal impairment. It has a low incidence of hypoglycemia compared to sulfonylureas.^[39]

Sulfonylureas

These generally well tolerated but because they stimulate endogenous insulin secretion, they carry a risk of hypoglycemia.^[38] Elderly patients, with DM who are treated with sulfonylureas have a 36% increased risk of hypoglycemia compared to younger patients.^[41] Glyburide is associated with higher rates of hypoglycemia compared to glipizide.^[42] Some of the risk factors for hypoglycemia are age-related impaired renal function, simultaneous use of insulin or insulin sensitizers, age greater than 60 years, recent hospital discharge, alcohol abuse, caloric restriction, multiple medications or medications that potentiate sulfonylurea actions.^[43] Use of long acting sulfonylurea such as glyburide should be avoided in elderly patients with DM and use of short-acting glipizide should be preferred.^[38]

Meglitinides

Repaglinide and nateglinide are non-sulfonylurea secretagogues which act on the ATP-dependent K-channel in the pancreatic beta cells thereby stimulating the release of insulin from the beta cells, similar to sulfonylurea, though the binding site is different.^[44] Meglitinides have a rapid onset and a short duration of action (4-6 hrs) and thus lower risk of hypoglycemia. Meglitinides are given before meals for postprandial blood glucose control. Pre-prandial administration allows flexibility in case a meal is missed without increased risk of hypoglycemia.^[45] Repaglinide is mainly metabolized in the liver with very minimal amounts excreted via the kidneys and thus dose adjustment is not necessary in patients with renal

insufficiency except those with end-stage renal disease.^[44]

Thiazolidinediones

Thiazolidinedione is an insulin sensitizer, selective ligands transcription factor peroxisomes proliferator-activated gamma. They are the first drugs to address the basic problem of insulin resistance in type 2 DM patients,^[46] whose class now includes mainly pioglitazone after the restricted use of rosiglitazone recommended by Food and Drug Administration (FDA) recently due to increased cardiovascular events reported with rosiglitazone.^[36] Pioglitazone use is not associated with hypoglycemia and can be used in cases of renal impairment and thus well tolerated in older adults. On the other hand, due to concerns regarding peripheral edema, fluid retention and fracture risk in women, its use can be limited in older adults with DM. Pioglitazone should be avoided in elderly patients with congestive heart failure and is contraindicated in patients with class III-IV heart failure.^[47]

Alpha-Glucosidase Inhibitors

Acarbose, Voglibose and Miglitol have not widely been used to treat type 2 DM individuals but are likely to be safe and effective. These agents are most effective for postprandial hyperglycemia and should be avoided in patients with significant renal impairment. Their use is usually limited due to high rates of side-effects such as diarrhoea and flatulence.^[38] Voglibose, which is the newest of the drugs, has been shown in a study to significantly improve glucose tolerance, in terms of delayed disease progression and in the number of patients who achieved normoglycemia.^[48]

Incretin-Based Therapies

Glucagon-like peptide 1 (GLP-1) analogues are the foundation of incretin-based therapies which are to target this previously unrecognized feature of DM pathophysiology resulting in sustained improvements in glycemic control and improved body weight control.^[49] They are available for use as monotherapy, as an adjunct to diet and exercise or in combination with oral hypoglycemic agents in adults with type 2 DM. Examples are Exenatide, an incretin mimetic, and Liraglutide.^[38]

There is no risk of hypoglycemia with the use of GLP-1 therapies (unless combined with insulin secretagogues). In addition, emerging evidence suggests incretin-based therapies may have a positive impact on inflammation, cardiovascular and hepatic health, sleep, and the central nervous system.^[49]

Dipeptidyl-Peptidase IV Inhibitors

Dipeptidyl-peptidase (DPP) IV inhibitors inhibit dipeptidyl peptidase-4 (DPP-4), a ubiquitous enzyme that rapidly inactivates both GLP-1 and GIP, increase active levels of these hormones and, in doing so, improves islet function and glycemic control in type 2 DM.^[50] DPP-4

inhibitors are a new class of anti-diabetogenic drugs that provide comparable efficacy to current treatments. They are effective as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. The DPP-4 inhibitors are well tolerated, carry a low risk of producing hypoglycemia and are weight neutral. However, they are relatively expensive.^[50] The long-term durability of effect on glycemic control and beta-cell morphology and function remain to be established.^[50,51]

Insulin

Insulin is used alone or in combination with oral hypoglycemic agents. Augmentation therapy with basal insulin is useful if some beta cell function remains. Replacement of basal-bolus insulin is necessary if beta cell exhaustion occurs. Rescue therapy using replacement is necessary in cases of glucose toxicity which should mimic the normal release of insulin by the beta cells of the pancreas.^[52] Insulin comes in injectable forms - rapid acting, short acting, intermediate acting and long acting. The long acting forms are less likely to cause hypoglycemia compared to the short acting forms.

Insulin analogues

Insulin therapy was limited in its ability to mimic normal physiologic insulin secretion. Traditional intermediate- and long-acting insulins (NPH insulin, lente insulin, and ultralente insulin) are limited by inconsistent absorption and peaks of action that may result in hypoglycemia.^[53,54] The pharmacokinetic profiles of the new insulin analogues are distinct from those of the regular insulins, and their onset and durations of action range from rapid to prolonged. Currently, two rapid-acting insulin analogues, insulin lispro and insulin aspart, and one long-acting insulin analogue, insulin glargine, are available.^[53,54]

Future in Drug Therapy Inhaled Insulin

The inhaled form of rapidly acting insulin which became available in 2006,^[55] after it was approved by both the European Medicines Evaluation Agency and FDA for treatment of type 1 and type 2 DM in adults.^[55-57] It is a rapid acting form of insulin that was indicated for use in adults with type 1 and type 2 DM and has the advantage of delivery directly into the lungs. Studies have however shown that inhaled insulin is as effective as, but not better than short acting insulin.^[55] It was withdrawn from the market by the manufacturer in October 2007 due to poor sales.

Bromocriptine

Quick-release bromocriptine has recently been developed for the treatment of type 2 DM. However, the mechanism of action is not clear. Studies have shown that they reduce the mean HbA1c levels by 0.0% to 0.2% after 24 weeks of therapy.^[58]

Others

Inhibitors of the sodium-glucose cotransporter 2, which increase renal glucose elimination, and inhibitors of 11 β -hydroxysteroid dehydrogenase 1, which reduce the glucocorticoid effects in liver and fat. Insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, and metabolic inhibitors of hepatic glucose output are being assessed for the purpose of development of new drug therapy for type 2 diabetic patients.^[59]

CONCLUSIONS

Type 2 DM is a metabolic disease that can be prevented through lifestyle modification, diet control, and control of overweight and obesity. Education of the populace is still key to the control of this emerging epidemic. Novel drugs are being developed, yet no cure is available in sight for the disease, despite new insight into the pathophysiology of the disease. Management should be tailored to improve the quality of life of individuals with type 2 DM.

REFERENCES

- Ahmed AM. History of diabetes mellitus. *Saudi Med J*, 2002. Apr; 23(4): 373-378 [PubMed] [Google Scholar]
- Diabetes mellitus history- from ancient to modern times. Available at <http://science.jrank.org/pages/2044/Diabetes-Mellitus.html> (accessed on 22nd July, 2011).
- Patlak M. New weapons to combat an ancient disease: treating diabetes. *FASEB J*, 2002. Dec; 16(14): 1853 10.1096/fj.02-0974bkt [PubMed] [CrossRef] [Google Scholar]
- Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). *Robbins and Cotran Pathologic basis of disease (7th ed)* 2005. Philadelphia, Saunders; 1156-1226. [Google Scholar]
- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. *Nature reviews endocrinology*. Available at: www.nature.com/uidfinder (Accessed 22nd December 2011) [PubMed]
- Genetic basis of type 1 and type2 diabetes, obesity, and their complications. *Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC*. www2.niddk.nih.gov/NR (Accessed 22nd December 2011).
- Azevedo M, Alla S. Diabetes in sub-saharan Africa: kenya, mali, mozambique, Nigeria, South Africa and zambia. *Int J Diabetes Dev Ctries*, 2008. Oct; 28(4): 101-108 10.4103/0973-3930.45268 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Global burden of diabetes. International Diabetes federation. *Diabetic atlas fifth edition 2011*, Brussels. Available at <http://www.idf.org/diabetesatlas> (Accessed 18th December 2011).
- Chamnan P, Simmons RK, Forouhi NG, Luben R, Khaw Ky, Wareham NJ et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the EPIC-Norfolk cohort: Implication for preventive strategies. Available at <http://care.diabetesjournal.org> (Accessed 19th December 2011). [PMC free article] [PubMed]
- Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*, 2001. Dec; 414(6865): 782-787 10.1038/414782a [PubMed] [CrossRef] [Google Scholar]
- Mbanya JC. The burden of type 2 diabetes mellitus in the African diaspora. Available at www.medscape.com/viewarticle/560718_2.
- Department of Health and Human Services. Centres for Disease Control and Prevention, 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (Accessed December, 20th 2011).
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimate for the year 2000 and projections for 2030. *Diabetes Care*, 2004; 27(5): 1047-1053. 10.2337/diacare.27.5.1047 [PubMed] [CrossRef] [Google Scholar]
- Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. *JAMA*, 2004. Jun; 291(21): 2616-2622 10.1001/jama.291.21.2616 [PubMed] [CrossRef] [Google Scholar]
- Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. *Am Fam Physician*, 2009. Jan; 79(1): 29-36 [PubMed] [Google Scholar]
- Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med*, 2001. Sep; 345(11): 790-797 10.1056/NEJMoa010492 [PubMed] [CrossRef] [Google Scholar]
- Prevalence of overweight and obesity among adults with diagnosed Diabetes United States, 1988-1994 and 1999-2000"Centers for Disease Control and Prevention (CDC) (November 2004) *MMWR. Morbidity and Mortality Weekly Report*; 53(45): 1066-1068. [PubMed]
- Barlow SE and the Expert committee Expert committee recommendations regarding the prevention, assessment and treatment of childhood and adolescent overweight and obesity: Summary report. *Paediatrics* 2007; 120: S164-S192 10.1542/peds.2007-2329C [PubMed] [CrossRef] [Google Scholar]
- Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, et al. Association of

- urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. *JAMA* 2008. Sep; 300(11): 1303-1310 10.1001/jama.300.11.1303 [PubMed] [CrossRef] [Google Scholar]
20. Rother KI. Diabetes treatment—bridging the divide. *N Engl J Med*, 2007. Apr; 356(15): 1499-1501 10.1056/NEJMp078030 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
 21. McCarthy MI. Genomics, type 2 diabetes, and obesity. *N Engl J Med*, 2010. Dec; 363(24): 2339-2350 10.1056/NEJMra0906948 [PubMed] [CrossRef] [Google Scholar]
 22. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. *Hum Mol Genet*, 2006. Oct; 15(Spec No 2): R124-R130 10.1093/hmg/ddl215 [PubMed] [CrossRef] [Google Scholar]
 23. Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E, EGIR (European Group for the Study of Insulin Resistance) Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. *Int J Obes Relat Metab Disord*, 1999; Dec; 23(12): 1307-1313 10.1038/sj.ijo.0801072 [PubMed] [CrossRef] [Google Scholar]
 24. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group The metabolic syndrome—a new worldwide definition. *Lancet*, 2005. Sep; 366(9491): 1059-1062 10.1016/S0140-6736(05)67402-8 [PubMed] [CrossRef] [Google Scholar]
 25. Powers AC. Diabetes mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). *Harrison's Principles of Internal Medicine*. 17th ed, New York, McGraw-Hill; 2008: 2275-2304. [Google Scholar]
 26. Jack L, Jr, Boseman L, Vinicor F. Aging Americans and diabetes. A public health and clinical response. *Geriatrics* 2004. Apr; 59(4): 14-17 [PubMed] [Google Scholar]
 27. Lovejoy JC. The influence of dietary fat on insulin resistance. *Curr Diab Rep* 2002. Oct; 2(5): 435-440 10.1007/s11892-002-0098-y [PubMed] [CrossRef] [Google Scholar]
 28. Kahn CR. Banting Lecture. Insulin action, diabetogenesis, and the cause of type II diabetes. *Diabetes* 1994. Aug; 43(8): 1066-1084 [PubMed] [Google Scholar]
 29. Robertson RP. Antagonist: diabetes and insulin resistance—philosophy, science, and the multiplier hypothesis. *J Lab Clin Med* 1995. May; 125(5): 560-564, discussion 565 [PubMed] [Google Scholar]
 30. Fujioka K. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. *JAAPA* 2007; suppl 3-8. [PubMed]
 31. Garcia-Roves PM. Mitochondrial pathophysiology and type 2 diabetes mellitus. *Arch Physiol Biochem* 2011. Jul; 117(3): 177-187 10.3109/13813455.2011.584538 [PubMed] [CrossRef] [Google Scholar]
 32. Cox EM, Elelman D. Test for screening and diagnosis of type 2 diabetes. *Clin Diabetes* 2009; 4(27): 132-138 10.2337/diaclin.27.4.132 [CrossRef] [Google Scholar]
 33. Harris MI, Klein R, Welborn TA, Knudman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. *Diabetes Care* 1992. Jul; 15(7): 815-819 10.2337/diacare.15.7.815 [PubMed] [CrossRef] [Google Scholar]
 34. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009; 32: 1-8 10.2337/dc09-S001 [CrossRef] [Google Scholar]
 35. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2007. Dec; 298(22): 2654-2664 10.1001/jama.298.22.2654 [PubMed] [CrossRef] [Google Scholar]
 36. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. *Lancet* 2006. Nov; 368(9548): 1681-1688 10.1016/S0140-6736(06)69703-1 [PubMed] [CrossRef] [Google Scholar]
 37. Boffetta P, McLerran D, Chan Y, Manami I, Sinha R, Gupta PC, et al. Body mass index and diabetes mellitus in Asia. A cross sectional pooled analysis of 900,000 individuals in the Asia cohort consortium 2011. Available at www.plosone.org/article/info (Accessed December 2011). [PMC free article] [PubMed]
 38. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. *Curr Opin Endocrinol Diabetes Obes* 2011. Apr; 18(2): 148-152 10.1097/MED.0b013e3283444ba0 [PubMed] [CrossRef] [Google Scholar]
 39. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodents skeletal muscle. *Am J Physiol Endocrinol Metab* 2006; 219(1): 182-189 10.1152/ajpendo.00272.2005 [PubMed] [CrossRef] [Google Scholar]
 40. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. *Diabetes* 2008. Feb; 57(2): 306-314 10.2337/db07-0381 [PubMed] [CrossRef] [Google Scholar]
 41. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. *J Clin Epidemiol* 1997. Jun; 50(6): 735-741 10.1016/S0895-4356(97)00024-3 [PubMed] [CrossRef] [Google Scholar]
 42. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. *J Am Geriatr*

- Soc* 1996. Jul; 44(7): 751-755 [PubMed] [Google Scholar]
43. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. *Drug Saf* 2005; 28(7): 601-631 10.2165/00002018-200528070-00004 [PubMed] [CrossRef] [Google Scholar]
 44. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. *Diabetes* 1998. Mar; 47(3): 345-351 10.2337/diabetes.47.3.345 [PubMed] [CrossRef] [Google Scholar]
 45. Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. *Diabetes Metab* 2006. Apr; 32(2): 113-120 10.1016/S1262-3636(07)70257-4 [PubMed] [CrossRef] [Google Scholar]
 46. Yki-Järvinen H. Thiazolidinediones. *N Engl J Med* 2004. Sep; 351(11): 1106-1118 10.1056/NEJMra041001 [PubMed] [CrossRef] [Google Scholar]
 47. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. *Am J Med* 1995. May; 98(5): 443-451 10.1016/S0002-9343(99)80343-X [PubMed] [CrossRef] [Google Scholar]
 48. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. *Lancet* 2009. May; 373(9675): 1607-1614 10.1016/S0140-6736(09)60222-1 [PubMed] [CrossRef] [Google Scholar]
 49. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. *J Diabetes* 2011. (published online ahead of print).
 50. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. *Curr Med Res Opin* 2007. Apr; 23(4): 919-931 10.1185/030079906X162746 [PubMed] [CrossRef] [Google Scholar]
 51. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int J Clin Pract* 2006. Nov; 60(11): 1454-1470 10.1111/j.1742-1241.2006.01178.x [PubMed] [CrossRef] [Google Scholar]
 52. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. *Am Fam Physician* 2004. Aug; 70(3): 489-500 [PubMed] [Google Scholar]
 53. Burge MR, Schade DS. Insulins. *Endocrinol Metab Clin North Am* 1997. Sep; 26(3): 575-598 10.1016/S0889-8529(05)70268-1 [PubMed] [CrossRef] [Google Scholar]
 54. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. *CMAJ* 2009. Feb; 180(4): 400-407 10.1503/cmaj.081180 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
 55. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biapart insulin for type 2 diabetes: a multicentre randomised trial. *Lancet* 2010. Jun; 375(9733): 2244-2253 10.1016/S0140-6736(10)60632-0 [PubMed] [CrossRef] [Google Scholar]
 56. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. *Health Technol Assess* 2007. Sep; 11(33): 1-126 [PubMed] [Google Scholar]
 57. Inhaled insulin and diabetes. Diabetes monitor. Information, education, and support for people with diabetes. Available at: www.diabetesmonitor.com/inhaled.htm (Accessed 21st December 2011).
 58. Mikhail N. Quick-release Bromocriptine for Treatment of Type 2 diabetes. *Curr Drug Deliv* 2011. (Published online ahead of print). [PubMed]
 59. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. *Lancet* 2011. Jul; 378(9786): 182-197 10.1016/S0140-6736(11)60207-9 [PubMed] [CrossRef] [Google Scholar]
 60. <https://www.healthdirect.gov.au/type-2-diabetes>